Equillium to present at investor conferences in november 2020

La jolla, calif., nov. 10, 2020 (globe newswire) -- equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that bruce steel, equillium's chief executive officer and krishna polu, m.d., equillium's chief medical officer, will present at two upcoming investor conferences in november 2020.
EQ Ratings Summary
EQ Quant Ranking